Author

F. M. Nunez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:host-pathogen & immune response· 1 Assay:proteomics· 1

Frequent Co-Authors

M. Edwards· 2 shared P. Kadiyala· 2 shared A. Comba· 1 shared A. J. Nicola Candia· 1 shared A. M. Sonabend· 1 shared A. Mujeeb· 1 shared A. Schwendeman· 1 shared A. Taher· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Edwards

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

H3.3-G34R Mutation-Mediated Epigenetic Reprogramming Leads to Enhanced Efficacy of Immune Stimulatory Gene Therapy in Diffuse Hemispheric Gliomas

M. B. Garcia Fabiani, S. Haase, K. Banerjee, Z. Zhu, B. McClellan, A. Mujeeb, Y. Li, C. E. Tronrud, M. L. Varela, M. E. J. West, J. Yu, P. Kadiyala, A. Taher, F. J. NUNEZ, M. S. Alghamri, , Sart

This study shows that H3.3-G34R mutations reprogram the tumor immune microenvironment in diffuse hemispheric gliomas, enhancing the efficacy of immune stimulatory gene therapy and leading to long-term survival in treated mice.

bioRxiv · Jun 13, 2023 · PreprintCancer Biology

Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity

P. Kadiyala, S. V. Carney, J. C. Gauss, M. Garcia-Fabiani, F. Nunez, F. M. Nunez, M. Alghamri, Y. Liu, M. Yu, D. Li, M. Edwards, J. J. Moon, A. Schwendeman, P. R. Lowenstein, M. Castro

This study shows that inhibiting 2-hydroxyglutarate in mIDH1 gliomas with ATRX/TP53 inactivation improves survival and induces anti-tumor immunity through immunological memory and reduced T-cell exhaustion.

bioRxiv · May 11, 2020 · PreprintImmunology